Sign Out
Women of child-bearing potential: In each case the benefits for the mother must be weighed against the risks for the child.
Pregnancy: There is a limited amount of data on the use of desferrioxamine in pregnant patients. Studies in animals (rabbits) have shown reproductive toxicity/teratogenicity (see Pharmacology: Toxicology: Non-Clinical Safety Data under Actions). The risk to the fetus/mother is unknown.
Desferrioxamine should be used during pregnancy only if the expected benefit outweighs the potential risk to the fetus.
Breast-feeding: It is not known whether desferrioxamine passes into the breast milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse drug reactions in breast-fed newborns/infants, a decision should be made whether to abstain from breast-feeding or to abstain from using the medicinal product, taking into account the importance of the medicinal product to the mother.
